BioRestorative Therapies Beat Consensus Estimates

BioRestorative Therapies (BRTX) reported a loss of $0.19 per share on revenue of $0.02 million for the first quarter ended March 2026. The consensus estimate was a loss of $0.30 per share on revenue of $0.05 million. The company beat consensus estimates by 36.67% while revenue fell 8.00% compared to the same quarter a year ago.

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The company's core programs consist of Disc/Spine Program and Metabolic Program. Disc/Spine Program consists of cell therapy candidate, brtxDISC(TM) is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow. Metabolic Program consists of ThermoStem(R), developing an allogeneic cell-based therapy to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. BioRestorative Therapies, Inc. is based in Melville, New York.